MoonLake Immunotherapeutics 8-K

What Happened

• MoonLake Immunotherapeutics (MLTX) filed a Form 8‑K on June 9, 2026 reporting that shareholders at the Annual Meeting approved an amendment and restatement of the company’s 2022 Equity Incentive Plan and elected the Class I director nominee, Spike Loy. The proxy statement for the meeting was filed April 21, 2026.
• The amended Plan increases the number of Class A Ordinary Shares available for awards, revises vesting and director compensation terms, and extends the Plan term.

Key Details

• Equity Plan changes: added 5,000,000 Class A Ordinary Shares to the Plan; removed liberal share recycling; added a one‑year minimum vesting requirement; revised non‑employee director compensation limits; extended Plan term to June 4, 2036.
• Director election: Spike Loy elected as Class I director — Votes For: 47,222,233; Votes Withheld: 3,889,131; Broker Non‑Votes: 10,761,142.
• Other shareholder votes: Auditor (Baker Tilly US, LLP) ratified — 61,831,463 For, 17,522 Against, 23,521 Abstain. Advisory vote on executive compensation — 50,365,168 For, 731,158 Against, 15,038 Abstain, 10,761,142 Broker Non‑Votes. Plan amendment approved — 50,599,032 For, 498,186 Against, 14,146 Abstain, 10,761,142 Broker Non‑Votes.
• The full Amended and Restated 2022 Equity Incentive Plan is filed as Exhibit 10.1 to the 8‑K.

Why It Matters

• For investors, the 5 million‑share increase expands the pool available for stock‑based awards, which can dilute existing shareholders over time as awards are granted and vested.
• The one‑year minimum vesting and removal of liberal share recycling limit how quickly and repeatedly shares can be reissued, which can moderate future dilution compared with more permissive plan features.
• Election of Spike Loy and ratification of the auditor are governance items that confirm board composition and auditor continuity; the advisory “say on pay” vote passed, indicating shareholder support for executive compensation as presented.